| Tokuda et al. [10] | Karakiewicz et al. [9] | Wright et al. [11] |
Publishing year Patients source Period of data extraction Number of patients Median follow-up time, months (range) Incidence (%)
CSS rate at 1 year, % CSS rate at 3 years, % Median age, years (range) Male gender, n (%) Symptomatic at presentation, n (%) Median tumor size, cm (range) Advance T stage (T3 - 4), n (%): Regional nodal involvement (N1-2), n (%): Distance Metastasis (M1), n. (%): High grade, n. (%): Fuhrmann G3 - 4 Poorly/undifferentiated Surgery for primary tumor, n. (%): Chemotherapy, n. (%) Immunotherapy, n (%) | 2006 Japan 2001-2003 81 15.0 (0.5 - 157.0) -
69.0% 45.3% 58.2 (26 - 79) 58 (71.6%) 53 (65.4%) 6 (1 - 15) 46 (57.0%) 27 (33.3%) 26 (32.1%)
80 (98.8%) - 80 (98.8%) 17 (21.0%) 34 (42.0%) | 2007 European 1984-2001 41 2.9 (0.1 - 19.7) 0.6%
86.1% †68.0% 64.0 (40 - 90) 31 (75.6%) 59 (72.8%) 6.1 (2.0 - 18.0) 33 (80.5%) 20 (48.8%) 8 (19.5%)
32 (78.0%) - 41 (100.0%) - - | 2009 USA 2001-2005 160 19.0 1.2% in Blacks 0.4% in Whites 70.0% 58.0% 62.0 (-) 112 (70%) - ‡5.9 (-) 53 (33.1%) 24 (15.0%) 44 (27.5%)
§70.0% 135.(84.4%) - - |